Financials in USD. Standardized financial statements.
A compact view of how Impel Pharmaceuticals Inc. turns revenue into operating income and net income.
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| Revenue? | $12.65M | $668,000 | $0 | $0 |
| Revenue Growth? | +1794.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $6.50M | $691,000 | $0 | $0 |
| Gross Profit? | $6.16M | -$23,000 | $0 | $0 |
| Gross Margin? | +48.7% | -3.4% | 0.0% | 0.0% |
| Operating Expenses? | $89.34M | $71.46M | $45.33M | $41.57M |
| Operating Income? | -$83.18M | -$71.49M | -$45.33M | -$41.57M |
| EBITDA? | -$91.28M | -$70.40M | -$44.26M | -$40.84M |
| Income Before Tax | -$106.31M | -$76.53M | -$45.80M | -$41.83M |
| Income Tax Expense | $23.13M | $2,000 | $1,000 | $30,000 |
| Net Income? | -$129.44M | -$76.54M | -$45.80M | -$41.86M |
| EPS? | $-5.52 | $-5.24 | $-3.49 | $-3.19 |
| Diluted EPS? | $-5.52 | $-5.24 | $-3.49 | $-3.19 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality